Pulmatrix enters cross license agreement with MannKind
PremiumThe FlyPulmatrix enters cross license agreement with MannKind
5M ago
Pulmatrix files $95M mixed securities shelf
Premium
The Fly
Pulmatrix files $95M mixed securities shelf
6M ago
Pulmatrix announces results from PUR3100 study
Premium
The Fly
Pulmatrix announces results from PUR3100 study
6M ago
Pulmatrix to Present at Investor Conferences, Limits Updates
PremiumCompany AnnouncementsPulmatrix to Present at Investor Conferences, Limits Updates
8M ago
Pulmatrix to stop patient enrollment of the Ph2b study of PUR1900
Premium
The Fly
Pulmatrix to stop patient enrollment of the Ph2b study of PUR1900
10M ago
Pulmatrix’s IND application for PUR3100 to treat acute migraine accepted by FDA
Premium
The Fly
Pulmatrix’s IND application for PUR3100 to treat acute migraine accepted by FDA
1y ago
Pulmatrix dosed first patient in Phase 2b trial of PUR1900
PremiumThe FlyPulmatrix dosed first patient in Phase 2b trial of PUR1900
2y ago
Pulmatrix announces ‘positive’ data from Phase 1 study of PUR3100
Premium
The Fly
Pulmatrix announces ‘positive’ data from Phase 1 study of PUR3100
2y ago
Pulmatrix Will Regain Full Rights To PUR1800 After Termination Of Licensing Agreement; Shares Fall 16%
Premium
Market News
Pulmatrix Will Regain Full Rights To PUR1800 After Termination Of Licensing Agreement; Shares Fall 16%
4y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100